Safety of Pemetrexed and Carboplatin with Radiation for Esophageal Cancer
Author Information
Author(s): Rajini Katipamula, Aminah Jatoi, Nathan R. Foster, Francis Nichols, Joseph Rubin, Matthew Callister, Leonard Gunderson, Steven Alberts
Primary Institution: Mayo Clinic
Hypothesis
The combination of pemetrexed, carboplatin, and radiation followed by surgery is safe for patients with locally advanced esophageal cancer.
Conclusion
The treatment regimen appears to be well tolerated and can be further studied in this clinical setting.
Supporting Evidence
- Only 1 of the 6 patients experienced a grade 4 adverse event.
- Three patients experienced at least one grade 3 adverse event.
- There were no deaths among the patients.
Takeaway
Doctors tested a new treatment for esophageal cancer on 6 patients, and it seemed safe with only a few side effects.
Methodology
Six patients received pemetrexed and carboplatin with radiation followed by surgery, and their safety was analyzed.
Limitations
The study only included a small number of patients (6), which limits the generalizability of the findings.
Participant Demographics
5 males, median age 67 years (range 52–75), all with adenocarcinoma.
Want to read the original?
Access the complete publication on the publisher's website